Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 13Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Myeloid 1CNS 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Medulloblastoma 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Diseases 1Glioma 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Novartis

Phase 1/2 Completed
76 enrolled 18 charts
CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡